Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD
Published: Friday, Jun 23, 2017



Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Cerdulatinib is an oral dual Syk/JAK inhibitor that is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent lymphomas such as follicular lymphoma and peripheral T-cell lymphoma.

This is an open-label, phase II cohort-driven expansion study, preliminary results of which are being presented at the 2017 European Hematology Association Congress.
 


Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Cerdulatinib is an oral dual Syk/JAK inhibitor that is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent lymphomas such as follicular lymphoma and peripheral T-cell lymphoma.

This is an open-label, phase II cohort-driven expansion study, preliminary results of which are being presented at the 2017 European Hematology Association Congress.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x